Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics.

A 5% decrease by the last dose was also evident for the combination of Glu and Gln ( p = 0.010, MD = −0.545 mmol/L, 95% CI = −0.951, −0.138) but fell short of significance for Glu itself ( p = 0.051, MD = −0.231 mmol/L, 95% CI = −0.462, 0.001).

also in 361 other papers

We showed that empagliflozin elevated circulating BHB levels after acute and chronic dosing, in agreement with a previous study of empagliflozin that showed a trend towards BHB elevation in a non-diabetic population [ 33 ].

also in 53,322 other papers